AbCellera Biologics Inc. (ABCL)
NASDAQ: ABCL · Real-Time Price · USD
3.530
+0.010 (0.28%)
At close: Mar 19, 2026, 4:00 PM EDT
3.530
0.00 (0.00%)
Pre-market: Mar 20, 2026, 6:04 AM EDT
AbCellera Biologics Employees
AbCellera Biologics had 562 employees as of December 31, 2025. The number of employees decreased by 34 or -5.70% compared to the previous year.
Employees
562
Change (1Y)
-34
Growth (1Y)
-5.70%
Revenue / Employee
$133,680
Profits / Employee
-$260,520
Market Cap
1.07B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 562 | -34 | -5.70% |
| Dec 31, 2024 | 596 | 10 | 1.71% |
| Dec 31, 2023 | 586 | 91 | 18.38% |
| Sep 30, 2023 | 630 | 155 | 32.63% |
| Jun 30, 2023 | 590 | 140 | 31.11% |
| Mar 31, 2023 | 525 | 125 | 31.25% |
| Dec 31, 2022 | 495 | 109 | 28.24% |
| Sep 30, 2022 | 475 | 115 | 31.94% |
| Jun 30, 2022 | 450 | 148 | 49.01% |
| Mar 31, 2022 | 400 | 194 | 94.17% |
| Dec 31, 2021 | 386 | 180 | 87.38% |
| Sep 30, 2021 | 360 | 186 | 106.90% |
| Jun 30, 2021 | 302 | 128 | 73.56% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Pharming Group | 404 |
| Geron | 258 |
| EyePoint | 214 |
| Inhibrx Biosciences | 161 |
| Precigen | 143 |
| Septerna | 130 |
| ORIC Pharmaceuticals | 104 |
| ArriVent BioPharma | 77 |
ABCL News
- 13 days ago - AbCellera Biologics Inc. (ABCL) Presents at TD Cowen 46th Annual Health Care Conference Transcript - Seeking Alpha
- 23 days ago - AbCellera Biologics Inc. (ABCL) Q4 2025 Earnings Call Transcript - Seeking Alpha
- 23 days ago - AbCellera Reports Full Year 2025 Business Results - Business Wire
- 5 weeks ago - AbCellera to Present at Upcoming Investor Conferences in March and April 2026 - Business Wire
- 2 months ago - AbCellera to Report Full Year 2025 Financial Results on February 24, 2026 - Business Wire
- 2 months ago - AbCellera Biologics Inc. (ABCL) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript - Seeking Alpha
- 2 months ago - AbCellera Announces First Patients Dosed in Phase 2 Portion of its Phase 1/2 Clinical Trial of ABCL635 for the Treatment of Vasomotor Symptoms Due to Menopause - Business Wire
- 3 months ago - AbCellera and Bruker Reach Global Settlement of Patent Litigation - Business Wire